PGR and ovarian carcinoma: OC’s ERα antagonism extends to ER+ endometrial and ovarian cancers, where it suppresses E2-induced IL-6/STAT3 cascades (70% IL-6 reduction at 25 μM) and downregulates progesterone receptor (PR) expression via GREB1 suppression [30].